1
Clinical Trials associated with COVID-19 CD40.RBDv(LinKinVax)A Phase 1/2 Multicenter, Randomized Study of the Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
The main questions that will be studied are :
Is the CD40.RBDv (adjuvanted or not) safe ?
Does the CD40.RBDv (adjuvanted or not) imply an immunologic response ? Participants will receive, depending on their randomization arm, 1 or 2 injections of the CD40.RBDv vaccine or a single injection of approved mRNA vaccine
100 Clinical Results associated with COVID-19 CD40.RBDv(LinKinVax)
100 Translational Medicine associated with COVID-19 CD40.RBDv(LinKinVax)
100 Patents (Medical) associated with COVID-19 CD40.RBDv(LinKinVax)
100 Deals associated with COVID-19 CD40.RBDv(LinKinVax)